Company intelligence / Profile preview

Oryx Isotopes

Dammam, Eastern Province, Saudi Arabia

Ownership: Private
Development stage: Other

Overview

Oryx Isotopes is a GMP- and ISO9001-certified radiopharmaceutical manufacturer established in 2021 in Dammam, Saudi Arabia, supplying diagnostic and therapeutic radioisotopes in Saudi Arabia and GCC countries. It has a strategic manufacturing and distribution partnership with Life Molecular Imaging for the PET tracer Florbetaben (18F) to support amyloid-PET imaging for Alzheimer's disease and other cognitive disorders across Saudi Arabia and the broader MENA region.[2][3][5][8]

Therapeutic areas: OncologyNeurology
Modalities: RadiopharmaceuticalRadiopharmaceutical (diagnostic)Radiopharmaceutical (therapeutic)
Industry: Biotech

Drug pipeline

1 asset

gallium-68 chloride

Unknown

Partnerships

Life Molecular Imaging

Beyond the preview

Go deeper on Oryx Isotopes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oryx Isotopes.

Explore the full profile